BCG vaccination reduces tau pathology and restores cognitive function

The Bacille Calmette-Guérin (BCG) vaccine limits neuroinflammation and enhances tau clearance in a tauopathy model.

BCG administration reduces hippocampal phospho-tau and microgliosis in PS19 mice. It also preserves neuronal markers.

In vivo volumetric T2-magnetic resonance imaging (MRI) showed attenuated brain atrophy. This was accompanied by increased glutamate-weighted chemical exchange saturation transfer-MRI signals.

BCG-treated mice showed improved performance in the novel object recognition test. They also showed improved body-weight maintenance and survival.

BCG induces systemic and central nervous system myeloid cell reprogramming. This process limits neuroinflammation and enhances tau clearance.

The findings indicate BCG is a safe, readily available therapy. It merits consideration as a preventive agent against dementia.

Key facts

  • BCG administration reduced hippocampal phospho-tau and microgliosis in PS19 mice.
  • BCG-treated mice showed improved performance in the novel object recognition test.
  • BCG induces myeloid cell reprogramming that limits neuroinflammation and enhances tau clearance.

All sections

Edition